The paper aims to develop a new concept for stratifying cancer patients using their biomarker profiles. The study leading to HCC only assessed the diagnostic aspect of recurrent cancer. However, the next clinical evaluations will be geared towards predicting recurrence. Thus, the finalized platform should make it possible to determine marker profiles in a clinical context and to develop a set of rules for predicting the progression of the pathology, more particularly of recurrence. Such a predictive tool would be beneficial for the management of patients with bladder cancer. Indeed, the latter has a high rate of recurrence and improving the determination of the risk of recurrence would allow optimal and personalized care for each patient (Ahram M, 2008). Finally, this concept of personalized medicine thanks to the information obtained by the analysis of several parameters on our platform can be applied to other cancers or pathologies.Individual markers could play a role important diagnostic or predictive, and this clinical utility in the laboratories clinical automated manner. The arrays of CpG methylation islands have allowed the identification of new individual epigenetic profile
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً